Humanigen Inc (HGENQ)

[archefal]

I don't think so, unfortunately. Part of CAR T administration is preconditioning w chemotherapy to lymphodeplete - i.e., kill the patient's "regular" immune cells so when the CAR T cells are reinfused, they have an evolutionary niche to expand into. Basically, they have more resources and less competition from their normal cells that are less effective at fighting the cancer. This sounds like the pt had some latent viral infections that reactivated upon lymphodepletion, probably taking advtg of the opportunity presented by attenuated immune surveillance. I don't know if lenz would help in this circumstance since it wasn't exactly CRS that killed them (resolved in 5 days)

Just my opinion, though. Happy to be proven wrong